Last updated: 11/03/2018 23:23:51
An Efficacy and Safety Study of Theraflu Day powder as Oral Solution for Cold and Flu
GSK study ID
205638
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Withdrawn
Withdrawn
Trial overview
Official title: An open-label, multicenter, randomized, parallel group, single-dose study to assess the short term efficacy and safety of paracetamol 500 mg + phenylephrine HCl 10 mg + vitamin C 200 mg powder for oral solution in subjects with symptoms of an upper respiratory tract infection
Trial description: The purpose of the study is to assess the short term efficacy of the Theraflu Aktiv powder for oral solution in the Russian population ascompared to an untreated group to support the indication of “Short term relief of the symptoms of colds, chills and influenza, including mild to moderate pain, fever and nasal congestion”.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Efficacy assessment
Timeframe: Baseline and 3 hours post dosing
Secondary outcomes:
Not applicable
Interventions:
Drug: Paracetamol, phenylephrine HCl, and vitamin C
Enrollment:
0
Observational study model:
Not applicable
Primary completion date:
2017-28-04
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Infections, Respiratory Tract
Product
ascorbic acid, paracetamol, paracetamol/ascorbic acid/phenylephrine, phenylephrine
Collaborators
Not applicable
Study date(s)
February 2017 to April 2017
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Participants must understand and provide written informed consent before any assessment is performed, understand the study procedures, and be willing and able to complete the required assessments
- Males and females ≥ 18 years
- Use of other investigational drugs within 30 days or 5 half-lives of enrollment,
- whichever is longer. Investigational drug refers to any drug being evaluated in clinical
Inclusion and exclusion criteria
Inclusion criteria:
- Participants must understand and provide written informed consent before any assessment is performed, understand the study procedures, and be willing and able to complete the required assessments
- Males and females ≥ 18 years
- Clinical diagnosis of a URTI as diagnosed by the investigator which would be classified as ICD-10 code J00 (acute nasopharyngitis common cold)
- Mild to moderate sore throat, i.e. rated as 1 or 2 on a 4-point ordinal scale (0=not present, 1= mild, 2=moderate, 3=severe), or headache (1, 2 or 3) or fever (less than 39°C ) or/and Nasal congestion (blocked nose): may be accompanied by rhinorrhea (runny nose) and/or sneezing
- Baseline Jackson TSS > 8
- Common cold symptoms for less than 48 hours
Exclusion criteria:
- Use of other investigational drugs within 30 days or 5 half-lives of enrollment, whichever is longer. Investigational drug refers to any drug being evaluated in clinical trials
- History of or known hypersensitivity to any of the study drugs, excipients or to drugs of similar chemical classes
- Sacharoze/maltose deficiency, fructose intolerance, glucosegalactose malabsorbtion
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL) or urine dipstick at baseline
- Any history of drug hypersensitivity, asthma, urticaria, or other significant allergic diathesis. participants with uncomplicated seasonal allergic rhinitis can be accepted if expected allergy season is clearly one month outside enrollment/ treatment period
- Any history of brain diseases, liver diseases or epilepsy
- Any evidence of uncontrolled cardiovascular (including hypertension), pulmonary, renal, hepatic, gastrointestinal, hematological, endocrinological, metabolic, neurological or psychiatric diseases at screening
- Subject has closed angle glaucoma, urinary retention, prostatic hyperplasia, pyloroduodenal obstruction, pheochromocytoma, diabetes mellitus
- A positive alcohol breath test or positive urine drug screen or a medical history data indicative of alcoholism, drug addiction, or drug abuse within the preceding 2 years
- Subject is current smoker of ≥10 cigarettes per day (or reports equivalent smoking habits using other tobacco products) and is unwilling to refrain from smoking while at the study site
- Subject is current smoker of ≥10 cigarettes per day (or reports equivalent smoking habits using other tobacco products) and is unwilling to refrain from smoking while at the study site
- Subject is taking or has taken within the last two weeks of dosing monoamine oxidase inhibitors, antidepressants, atropine, beta-blocking or sympathomimetic drugs desferrioxamine, hepatotoxic drugs, drugs inducing liver microsomal enzyme, (such as phenytoin, carbamazepine, isoniazid and rifampicin), neuroleptic drugs, chlorzoxazone, CNS depressant drugs including barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives, antipsychotics or is anticipated to require any of these medications at any time throughout the study
- Subject has used: Systemic or topical corticosteroids (with the exception of HRT and contraceptive steroids for females), within 3 weeks prior to dosing or Slow-release steroids (with the exception of HRT and contraceptive steroids for females) within 90 days prior to dosing
- Subject has used any of the following medications within 6 hours before first study drug administration, or is anticipated to use any of these medications at any time throughout the study: Any inhaler, medicated confectionary, throat lozenges, throat pastilles, sprays, any products with demulcent properties such as chewing gums and boiled sweets or mints, Any medication for sore throat containing a local anesthetic, Cold products and oral nasal decongestant products, Paracetamol or any NSAID
- Subject has used substances of abuse, herbal medicines, antihistamines and homeopathic medicine within 72 hours of dosing or is anticipated to require any of these drugs at any time throughout the study
- Subject was previously enrolled into the current study
- Persons directly or indirectly involved in the execution of this protocol, including first-degree relative of a study investigator, employees of the clinical study site, employees of the CRO and persons related to them
- “Vulnerable” individual (as defined by the IRB e.g. incarcerated person)
Trial location(s)
No location data available.
Study documents
No study documents available.
Results overview
Study Results yet to be posted
Recruitment status
Withdrawn
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website